Pharma unit helps boost profits at Bayer

pharmafile | July 27, 2016 | News story | Research and Development, Sales and Marketing |ย ย Bayer, Q2, resultsย 

The pharmaceutical division at Bayer was the driving force, as the company announced a 5.7% increase in second quarter profit and core earnings per share from continuing operations advanced by 4%.

The company, which is in the process of trying to acquire agri rival Monsanto, saw sales of prescription medicines rise 5.5% to โ‚ฌ4.1 billion, with recently launched products playing a significant role. Between them, oral anticoagulant Xarelto, eye medicine Eylea and cancer drugs Xofigo, Stivarga and Adempas generated combined sales of โ‚ฌ1.3 billion. Sales of Xarelto, alone, rose 30%.

Earnings before interest, taxes, depreciation and amoritisation in the pharmaceutical unit rose 13.3% to โ‚ฌ1.35 billion in Q2.

Advertisement

The company continues to plan sales of approximately โ‚ฌ35 billion for the year, excluding subsidiary Covestro, with โ‚ฌ16 billion coming from the pharma division. In consumer health and crop science, Bayer has revised its estimates down.

Its agri science business could be set for a massive boost as the company continues its pursuit of main rival Monsanto. The last bid of $64 billion was rejected earlier this month. At the time, the company indicated its commitment to continuing its pursuit of Monsanto.

Bayer CEO Werner Baumann says: โ€œOur life science businesses recorded encouraging sales and earnings growth overall. We remain confident about the year as a whole and are raising the group forecast.โ€

At the time of writing, Bayerโ€™s stock had risen 1.5%.

Sean Murray

Related Content

Evotec and Bayer announce new kidney disease study

Evotec and Bayer have announced the initiation of a phase 2 clinical study in kidney …

Third application for Orionโ€™s prostate cancer drug submitted by partner Bayer

Finnishย pharmaceutical company Orion has announced that its partner Bayer is applying for a third application …

Bayer and Evotec to collaborate on precision cardiology

Bayer and Evotec have announced that they have updated the focus of their collaboration to …

The Gateway to Local Adoption Series

Latest content